PerkinElmer has entered into an agreement to acquire Nexcelom Bioscience for US$260 million. The transaction is expected to close during the second quarter of 2021.
Nexcelom provides automated cell counting instruments and aids in the development of cell and gene and immuno-oncology therapies, virology drugs and vaccines. Its expected 2021 revenues are approximately US$40 million.
Commenting on the transaction, Prahlad Singh, President and Chief Executive Officer of PerkinElmer said: “We are looking forward to bringing Nexcelom’s expertise and technologies in drug development together with our passion and solutions for drug discovery. This combination will expand our efforts to help academic, government and biopharmaceutical organisations streamline their complete workflows and support efforts to accelerate time to target and time to market for novel therapies.”
Dr. Peter Li, President and Chief Executive Officer of Nexcelom added: “Our team is very excited to be joining forces with PerkinElmer to help scientists resolve some of today’s most pressing health challenges through modernising cell based assays using the most advanced cell models. Our organisation has a deep commitment to innovation and we are looking forward to continuing to grow our technology and customer footprint in combination with PerkinElmer’s strong global presence and infrastructure.”
